Laura Mercatali

Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts.

Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides.

Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.

Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.

Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model.

Pathogenesis of osteoblastic bone metastases from prostate cancer.

Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis.

Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.

Bone metastases detection by circulating biomarkers: OPG and RANK-L.

The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis.

Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.

Multiple marker detection in peripheral blood for NSCLC diagnosis.

Metastatic bone disease in the era of bone-targeted therapy: clinical impact.

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

What can we learn from the ZOOM trial?--Authors' reply.

Bone and cancer: the osteoncology.

Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis.

A new emergency in oncology: Bone metastases in breast cancer patients (Review).

CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.

The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin.

ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling.

Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report.

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).

[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.

RANKL: A promising circulating marker for bone metastasis response.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of (18)FDG-PET/CT.

Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Management and potentialities of primary cancer cultures in preclinical and translational studies.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.